Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

By afschroeder • October 24, 2025

Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025 Oct 21:S1556-0864(25)02856-4. doi: 10.1016/j.jtho.2025.10.009. Epub ahead of print. PMID: 41130408.

Tags: Cardiology/Epi, EGFR, MET (min 3), NSCLC, Osimertinib, Publications, Savolitinib (max 5)

New-Onset Atrial Fibrillation as a Predictor of Cancer: Insights from a Real-World Dataset

Alzahrani A, Gokul K, Paleri A, Powers EM, Bailin S, Yang EH, Fradley M, Farjo P, Dominic P. New-Onset Atrial Fibrillation as a Predictor of[...]

The REgistry of Flow and Perfusion Imaging for Artificial Intelligence with positron emission tomography (REFINE PET):Rationale and design

Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Miller RJH, Kavanagh PB, Liang JX, Dey D, Slipczuk L, Travin MI, Alexanderson E, Carvajal-Juarez I, Packard[...]

Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial

Lindman BR, Pibarot P, Schwartz A, Cohen DJ, Giustino G, Oldemeyer JB, Strote JA, Babaliaros V, Devireddy CM, Fearon WF, Fischbein MP, Daniels D, Spies[...]